The present invention relates to a solid dosage form comprising a solid dispersion composition of at least one HIV protease inhibitor and a water-soluble polymer having a glass transition temperature (Tg) of at least about 50° C. in an amount of less than 50% by weight of the dosage form. It also relates to a process of preparation for such solid dosage forms.